Aerosols and devices

Respiratory Care Clinics of North America

Volumn 7, Issue 2, 2001, Pages 131-173

  Dolovich, Myrna B ^a   Fink, James B ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b AeroGen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIINFECTIVE AGENT; BRONCHODILATING AGENT; BUDESONIDE; CALCITONIN; GROWTH FACTOR; INSULIN; PEPTIDE DERIVATIVE; PROTEIN DERIVATIVE; STEROID; TERBUTALINE SULFATE;

AEROSOL; ARTICLE; ASTHMA; BIOTECHNOLOGY; BREATHING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY POWDER; FLOW RATE; HUMAN; LUNG DISEASE; LUNG PARENCHYMA; METERED DOSE INHALER; NEBULIZER; PARTICLE SIZE; RESTRICTIVE LUNG DISEASE; VELOCITY; WETTABILITY;

EID: 0035182034     PISSN: 10785337     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-5337(05)70029-0     Document Type: Article

References (195)

1. Production and characterization of aerosols
2. Respiratory Drug Delivery
3. Aerosols for delivery of therapeutic and diagnostic agents and the respiratory tract
4. Aerosols: Generation, methods of administration and therapeutic applications in asthma
5. Aerosols in diagnosis: Ventilation, airway penetrance, airway reactivity, epithelial permeability and mucociliary transport
6. The use of radioactive aerosols in the diagnosis of lung disease
7. Aerosols as diagnostic tools
8. Bronchial responsiveness to histamine or methacholine in asthma: Measurement and clinical significance
9. Airway challenge with inhaled constrictor mediators
10. Ventilation scanning with technetium labelled aerosols: DTPA or sulphide colloid?
11. Methodologic consideration in mucociliary clearance and lung epithelial absorption measurements
12. Characterization of 3 systems used to deliver pentamidine (P) aerosol
13. Delivery of DNA-cationic liposome complexes by small-particle aerosol
14. Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles
15. Aerosol Measurement: Principles, Techniques and Applications
16. Airflow dynamics in the human airways
17. Pathophysiological and disease constraints on aerosol delivery
18. Aerosol penetrance: A sensitive index of peripheral airways obstruction
19. Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics
20. Physical factors determining particle deposition in the human respiratory tract
21. Regional deposition of particles in the human respiratory tract
22. Aerosol penetration to the lungs: Influence on airway response
23. Effect of nebulized aerosol size on lung deposition in patients with mild asthma
24. Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma
25. Aerosol characterization and deposition
26. Aerosol generation concepts and parameters
27. Generation and use of monodisperse aerosols
28. An evaluation of the physical properties of monodisperse and heterodisperse aerosols used in the assessment of bronchial function
29. Deposition of aerosol in the respiratory tract
30. Particle size of therapeutic aerosols
31. Recommendations of the USP advisory panel on aerosols on the USP general chapters on aerosols [601] and uniformity of dosage units [905]
32. Effect of random airway sizes on aerosol deposition
33. Task group on lung dynamics: Deposition and retention models for internal dosimetry of the human respiratory tract
34. Physical properties and mechanisms of deposition of aerosols
35. A comparison of submicronic technetium aerosol with xenon 127 for ventilation studies
36. Pulmonary deposition of nebulized pentamidine isethionate: Effect of nebuliser type, dose, and volume of fill
37. Factors determining pulmonary deposition of aerosolized pentamidine in patients with human immunodeficiency virus infection
38. Epithelial permeability
39. Deposition of inhaled aerosols
40. Electrostatic lung deposition experiments with humans and animals
41. On the practical significance of electrostatic lung deposition of isometric and fibrosis aerosols
42. Deposition of electrically charged drug aerosols
43. Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation, and avoiding multiple actuations of drug
44. Optimal delivery of aerosols from metered dose inhalers
45. Depsoition in man of particles inhaled in air or helium-oxygen mixture at different flow rates
46. Pulmonary deposition and retention of inhaled aerosols
47. Regional aerosol deposition in the human respiratory tract
48. Total deposition of aerosol particles in the human respiratory tract for nose and mouth breathing
49. Experimental measurement and empirical modelling of the regional deposition on inhaled particles in humans
50. Calculated deposition of inhaled particles in the airway generations of normal subjects
51. A semi-empirical model of aerosol deposition in the human respiratory tract for mouth inhalation
52. Inhaled drugs and the lung
53. Comparative measurement of lung deposition of inhaled fine particles in normal subjects and patients with obstructive airway disease
54. Inhalation devices and technique
55. Measurement of bronchial hyperreactivity in infants and preschool children using a new method
56. The influence of age on aerosol deposition in children with cystic fibrosis
57. How much aerosol reaches the lungs of wheezy infants and toddlers?
58. Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia
59. New aerosol delivery system for neonatal ventilator circuits
60. Deposition pattern of radiolabeled salbutamol inhaled from a metered-dose inhaler by means of a spacer with mask in young children with airway obstruction
61. Aerosols and humidity therapy: Generation and respiratory deposition of therapeutic aerosols
62. The size of soluble aerosol particles as a function of the humidity of the air: Application to the human respiratory tract
63. Factors determining hygroscopic aerosol deposition in airways
64. The role of particle hygroscopicity in aerosol therapy and inhalation toxicology
65. Aerosol delivery during mechanical ventilation: A predictive in-vitro lung model
66. Estimation of the deposition of aerosolized drugs in the human respiratory tract due to hydroscopic growth
67. New delivery systems and propellants
68. The generation of aerosols of fine particles
69. Properties of aerosols produced by several jet and ultrasonic nebulizers
70. Effect of auxiliary airflow on the output characteristics of compressed air nebulizers
71. Nebuliser performance, pharmacokinetics, airways, and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream")
72. Aerosol Dosage forms and formulation
73. Droplets produced by medical nebulizers. Some factors affecting their size and solute concentration
74. Electronically controlled drug delivery systems based on piezo electric crystal
75. Jet and ultrasonic nebuliser output: Use of a new method for direct measurement of aerosol output
76. Operating characteristics of some compressed air nebulizers
77. Assessment of jet nebulizers for lung delivery
78. 99mTc-DTPA
79. Standardization of inhalation provocation tests: Influence of nebulizer output, particle size and method of inhalation
80. Efficiency of air compressor-driven nebulizers
81. Medication-delivery performance of 8 small-volume hand-held nebulizers: Effects of diluent volume, gas flowrate, and nebulizer model
82. Factors influencing the size distribution of aerosols from jet nebulizers
83. Inaccurate calculation of drug output from nebulisers
84. Behavior of nebulizing solutions and suspensions
85. Drug delivery systems
86. Assesment of aerosol delivery systems for recombinant human deoxyribonuclease
87. Operating characteristics of eighteen different continuous-flow jet nebulizers with beclomethasone dipropionate liposome aerosol
88. Disposable jet nebulizers: How reliable are they?
89. Inhalers and nebulizers: Which to choose and why
90. Pulmonary deposition of a nebulised aerosol during mechanical ventilation
91. Effect of a spacer in pulmonary aerosol deposition from a jet nebuliser during mechanical ventilation
92. Toxicologic responses to inhaled aerosols and their ingredients
93. Adverse reactions to the non-drug constituents of nebulizer solutions
94. Regional deposition of saline aerosols of different tonicities in normal and asthmatic subjects
95. Some technical factors influencing the induction of sputum for cell analysis
96. Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream")
97. The delivery of budesonide suspension via small volume nebulizers: A comparative in vitro assessment
98. Halolite: A novel liquid drug aerosol delivery system
99. New propellant-free technologies under investigation
100. AERx-development of a novel liquid aerosol delivery system: Concept to clinic
101. Physical chemical and physiological factors influencing the effectiveness of inhaled insulin
102. The AERx aerosol delivery system
103. Bolus delivery of morphine solutions with the AERx pain management system (PMS)
104. Deposition of radiolabelled protein from AERx in patients with asthma
105. The AeroDose multidose inhaler device design and delivery characteristics
106. Albuterol sulphate delivery from the AeroDose liquid inhaler
107. Efficient delivery to the lungs of Flunisolide Aerosol from a new portable hand-held multi-dose nebulizer
108. Lung and oropharyngeal depositions of fenoterol hydrobromide delivered from the prototype III hand-held multidose Respimat nebuliser
109. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: Comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices
110. Boehringer Ingelheim nebulizer BINEB TM a new approach to inhalation therapy
111. Dose-ranging finding study comparing a new soft mist inhaler with a conventional metered dose inhaler (MDI) to deliver fenoterol in patients with asthma
112. Combination fenoterol/ipratropium bromide delivered via a new soft mist inhaler: Dose-range finding study in patients with asthma, in comparison with a conventional metered dose inhaler (MDI)
113. Drug delivery characteristics of metered-dose inhalers
114. Paradoxical bronchoconstriction in asthmatic patients after metered dose inhaler
115. Cough and wheezing from beclomethasone aerosol
116. Salbutamol metered dose aerosol induces epithelial airway lesions in intubated rabbits
117. Enhanced drug delivery through reformulating MDIs with HFA propellants-drug deposition and its effect on preclinical and clinical programs
118. Clinical equivalence of a novel non-chlorofluorocarbon-containing salbutamol sulfate metered-dose inhaler and a conventional chlorofluorocarbon inhaler in patients with asthma
119. The Science and Technology of Aerosol Packaging
120. Size aspects of metered-dose inhalers
121. Pressurized pharmaceutical aerosols in inhalation therapy I
122. Measurement of particle size characteristics of metered dose inhalers
123. Influence of formulation on aerosol particle size
124. Bronchodilator delivery from Gentlehaler, a new low-velocity pressurized aerosol inhaler
125. The use of the chlorofluorcarbon free salbutamol preparation, Airomir, with different spacer devices
126. How to formulate aerosols to obtain the desired spray pattern
127. MDIs: Physics of aerosol formulation
128. Studies of factors controlling the action of hair sprays: The influence of particle velocity and diameter on the capture of particles by arrays of hair fibres
129. Video characterization of flume patterns of inhalation aerosols
130. High speed photographic analysis of aerosols produced by metered dose inhalers
131. Low first-spray drug content in albuterol metered-dose inhalers
132. Problems patients have using pressurized aerosol inhalers
133. Use and misuse of metered-dose inhalers by patients with chronic lung disease
134. Drug deposition of pressurized inhalation aerosols: Influence of actuator tube design
135. New method of beclomethasone administration to children under 4 years of age
136. Design and Characteristics of a Portable Breath-Actuated Particle Size Selective Medical Aerosol Inhaler
137. Basis of an improved metered aerosol delivery system
138. Pressure flow characteristics of the valve in spacer devices
139. In vitro comparison of CFC and HFA salbutamol generics administered via small spacers
140. Effect of a pause prior to inhaling a MDI aerosol on drug availability through an open tube spacer
141. Improvement of pressurized aerosol deposition with Nebuhaler spacer device
142. Aerosol delivery through an open tube spacer: Importance of inhalation technique
143. Relative efficiency of four metered dose inhaler (MDI) holding chambers (HC) compared to albuterol MDI
144. Oropharyngeal deposition and delivery aspects of metered dose inhaler aerosols
145. Clinical evaluation of a simple demand inhalation MDI aerosol delivery device
146. Salbutamol aerosol delivery on man with the Rondo spacer
147. Oral pharyngeal candidiasis in patients treated with beclomethasone dipropionate delivered by metered-dose inhaler alone and with aerochamber
148. A large volume spacer significantly reduces the effect of inhaled steroids on bone formation
149. Characterization of medical aerosols: Physical and clinical requirements for new inhalers
150. Multiple actuations of salbutamol MDI reduce the amount of drug recovered in the respirable range
151. A non-electrostatic spacer for aerosol delivery
152. Comparison of performance of aluminum with plastic holding chambers with four drugs used in inhalation therapy
153. Differences in output from corticosteroid inhalers used with a volumatic spacer
154. Differences in aerodynamic particle size distributions of innovator and generic beclomethasone dipropionate aerosols used with and without a large volume spacer
155. Dry powder inhalers
156. The effect of air flow and carrier size on the characteristics of an inspirable cloud
157. The generation of respirable clouds from coarse powder aggregates
158. Salbutamol doses inhaled via Turbuhaler gives a better bronchodilating effect than when given via a pressurized metered dose inhaler
159. Performance-modifying influences in dry powder inhalation systems
160. Delivery characteristics of albuterol powder aerosol by rotahaler
161. Dose emissions from marketed dry powder inhalers
162. Need for a comparative performance standard for dry powder inhalers
163. Impaction and impingement techniques for powder inhalers-comparisons, problems and validation
164. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-implications for in vitro testing
165. Effect of powder inhaler resistance upon inspiratory profiles in health and disease
166. Drug delivery to the respiratory tract using dry powder inhalers
167. Critical aspects of the function of inspiratory flow driven inhalers
168. Dose targeting for dry powder inhalers
169. Letter to the Editor: Effect of exposure to humidity on terbutaline delivery from turbuhaler dry powder inhalation devices
170. Effect of relative humidity on particle size distribution from Turbuhaler
171. Simulated 'in-use' and 'mis-use' aspects of the delivery of terbutaline sulphate from the Bricanyl Turbuhaler™ dry powder inhalers
172. Testing of dry powder aerosol formulations in different environmental conditions
173. The Diskus: A new multi-dose powder device-efficacy and comparison with Turbuhaler
174. Terbutaline sulphate Turbuhaler: Effect of inhaled flow rate on drug deposition and efficacy
175. Inhalation technique and inhalation devices
176. 7 dry powder inhaler
177. Future propects for pulmonary delivery of drugs
178. Formulation and in vitro performance of liposome powder aerosols
179. Preliminary study of efficacy of insulin aerosol delivered by oral inhalation in diabetic patients
180. Liposomes and viruses for gene therapy of cystic fibrosis
181. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-implications for in vitro testing
182. Aerosol generation from dry powder inhalers: Can they equal metered-dose inhalers?
183. In-vitro comparison of the dose delivery characteristics of two multi-dose powder inhalers delivering long-acting β2-agonists
184. Lung deposition of albuteral sulphate from the Dura dryhaler in normal adults
185. Gamma scintigraphic evaluation of dry powder beclomethasone dipropionate (BDP) from an investigational Spiros Inhaler: Effect of inspiratory flow profile on pulmonary drug deposition
186. A comparison of the lung deposition of salbutamol inhaled from a new dry powder inhaler, at two inhaled flow rates
187. Pulmonary deposition of 99mTc-labelled salbutamol particles in healthy volunteers after inhalation from a metered-dose inhaler and from a novel multiple-dose inhaler
188. Dose variation, within and between individuals, with different inhalation systems
189. Lung deposition of budesonide in asthmatics: A comparison of different formulations
190. Effect of inhalation flow profiles on the deposition of radiolabelled BDP from a novel dry powder inhaler (DPI, Clickhaler TM), a conventional metered dose inhaler (MDI) and MDI plus spacer
191. Pharmacokinetics of fluticasone propionate inhaler from the Diskhaler and Diskus powder devices in healthy volunteers
192. Pharmacokinetics of fluticasone propionate inhaled from the Diskhaler$T$ and the Diskus$T$ powder devices in asthmatic patients
193. Scintigraphic assessment of drug delivery from the Ultrahaler dry powder inhaler